MedTrace Logo

I-125 Versus Pd-103 for Low Risk Prostate Cancer

NCT00494039 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 602

Last updated 2007-06-29

No results posted yet for this study

Summary

Objective: To test the hypothesis that the shorter half-life of Pd-103 versus I-125, will increase the rate of tumor eradication.

Research design A total of 600 patients with AJC clinical stage T1c-T2a prostatic carcinoma (Gleason grade 2 to 6, PSA 4 to 10 ng/ml) will be randomized to implantation with I-125 (160 Gy) versus Pd-103 (115 Gy).

Conditions

Interventions

PROCEDURE

Radioactive seed implant to prostate

Sponsors & Collaborators

  • Schiffler Cancer Center

    collaborator OTHER

  • VA Puget Sound Health Care System

    lead FED

Principal Investigators

  • Kent E Wallner, MD · Puget Sound Health Care system

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00494039 on ClinicalTrials.gov